Pegvaliase · PALYNZIQ

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Phenylketonuria

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Treatment of phenylketonuria
Product first approved 2023PMDA
EU
  • Phenylketonuria in patients aged 16 years and older
Product first approved 2019EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Phenylketonuria
Phase 2 (1)
Phenylketonuria
NCT01560286 · BioMarin Pharmaceutical
2012-05 – 2015-07 · Phenylketonuria
What this study did
Phase 4 (2)
Phenylketonuria
NCT07477691 · BioMarin Pharmaceutical
2026-05-29 – 2027-09-30 · Phenylketonuria
What this study did
NCT06780332 · BioMarin Pharmaceutical
2025-02-07 – 2026-08-17 · Phenylketonuria, PKU
What this study did

Competitive landscape

This drug's own stage for Phenylketonuria: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pegvaliase (PALYNZIQ): this drugApprovedProtein / enzyme therapeuticPhenylalanine ammonia lyase (enzyme substitution)Weak signalFeatured results are safety only in this race
Sapropterin Dihydrochloride (Kuvan)ApprovedSmall moleculePhenylalanine hydroxylase (PAH)Reliable signal
NCT00104247: Change in Blood Phenylalanine Levels From Baseline to Week 6. (baseline to week 6): Sapropterin Dihydrochloride — Baseline Blood Phe Level: 843 micromole per liter (Standard Deviation 300); Week 6 Blood Phe Level: 607 micromole per liter (Standard Deviation 377); Mean Change in Blood Phe from Baseline to Week 6: -239 micromole per liter (Standard Deviation 38) | Placebo — Baseline Blood Phe Level: 888 micromole per liter (Standard Deviation 323); Week 6 Blood Phe Level: 891 micromole per liter (Standard Deviation 348); Mean Change in Blood Phe from Baseline to Week 6: 6 micromole per liter (Standard Deviation 36)
NCT00272792: Phenylalanine supplement tolerated at week 10: sapropterin 20.9 (SD 15.4) vs placebo 2.9 (SD 4.0) mg/kg/day; mean difference 17.7 (SE 4.5) mg/kg/day, P<.001 (n=33 and 12) (Trefz et al., J Pediatr 2009).
SepiapterinApprovedSmall moleculePhenylalanine hydroxylase (PAH)Reliable signalNo reviewed efficacy summary in this indication
BEAM-304
—(overall)
Gene therapy / editingPAH gene (phenylalanine hydroxylase)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow PALYNZIQ (Pegvaliase) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Phase 4PhenylketonuriaRecruiting
Est. primary completion 2027-09-30 · NCT07477691 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

June 2026ApprovalEuropean Commission approves Palynziq for adolescents with PKU
EU, European Commission · Source ↗
27 February 2026ApprovalFDA approves PALYNZIQ for ages 12 and older
US, FDA · BioMarin Pharmaceutical · Source ↗
29 October 2025Filing acceptedFDA accepts sBLA for priority review (adolescents)
US, FDA · BioMarin Pharmaceutical · Source ↗
2 April 2025Topline resultPEGASUS phase 3 topline
BioMarin Pharmaceutical · Source ↗